Radio Netics is a company that specializes in providing digital audio solutions, including internet radio, music streaming, and podcast services.

Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals. 

5AM Ventures

Frazier Healthcare Partners

GordonMD Global Investments

Crinetics Pharmaceuticals

DCVC Bio

Frazier Life Sciences

Radionetics Oncology

Radionetics Oncology announces participation in Goldman Sachs Healthruption: Third Anual Healthcare Disruption Conference

Connect with Paul Grayson or Brett Ewald for an in-person meeting at  #jpm2024 
www.radionetics.com


Welcome Paul Grayson! We are thrilled to have you in the team!
www.radionetics.com

We continue to push forward an exciting pipeline of first-in-class targets for #radiopharmaceuticals with the support of our partners Frazier Life Sciences, 5AM Ventures,Crinetics Pharmaceuticals, DCVC Bio, GordonMD® Global Investments LP 
www.radionetics.com 

Our warmest wishes for a happy holiday season and a very happy 2024

COM:RADIONETICS

Radio Netics

Analysis Not Available